Cancer of Cervix Clinical Trial
Official title:
Evaluation of the Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on the 24-month Recurrence Rate in Locally Advanced Cervical Cancer
Overexpression of inhibitors of apoptosis proteins (IAPs) in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy may have a prognostic role on the local recurrence rate at 24 months.
Cervical cancer remains one of the most common cancers in women in terms of both incidence and mortality. Human Papilloma Virus carriage is a necessary condition for the development of these cancers but is not the only factor responsible for malignant transformation. Numerous molecular alterations come into play in the development of these tumours, involving the activation of oncogenes or the inactivation of tumour suppressor genes. Treatment of locally-advanced cancer is based on radiotherapy or a combination of radiotherapy and chemotherapy. Responses to anti-neoplastic treatments remain very heterogeneous from one woman to another. Predicting the response to these treatments would make it possible to envisage early therapeutic alternatives for patients identified as not very sensitive to standard treatments. IAPs (inhibitors of apoptosis proteins), which include XIAP, cIAP1 and cIAP2, are proteins involved in many cancers and capable of downregulating tumour cell apoptosis. It seems justified to investigate the role of these IAPs in resisting apoptosis-inducing anti-neoplastic treatments such as chemotherapy or radiotherapy. The aim of our study is to assess the prognostic role of overexpression of IAPs in locally advanced cervical cancer treated exclusively with radio-chemotherapy. This research seems all the more important as IAP-inhibiting molecules are currently being studied in other types of cancer (ear, nose and throat cancers) and appear to have a very encouraging radiosensitising effect. The hypothesis is that overexpression of IAPs in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy has a prognostic role on the local recurrence rate at 24 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03653819 -
High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs
|
N/A | |
| Active, not recruiting |
NCT00193739 -
Neoadjuvant Chemotherapy Followed by Surgery Versus Concurrent Chemoradiation in Carcinoma of the Cervix
|
Phase 3 | |
| Not yet recruiting |
NCT04999696 -
Minimally Invasive Therapy Versus Open Radical Hysterectomy for Management of Early Stage Cervical Cancer
|
N/A | |
| Completed |
NCT02309658 -
Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients
|
Phase 2 | |
| Completed |
NCT00193752 -
Para-Aortic Lymph Nodal Staging & Evaluation of Treatment Outcome by 18F FDG-PET in Advanced Cancer Cervix
|
N/A | |
| Recruiting |
NCT00154479 -
The Correlation Between the Haplotype of Human Leukocyte Antigen (HLA) and Human Papillomavirus
|
N/A | |
| Recruiting |
NCT05179824 -
Tempus Priority Study: A Pan-tumor Observational Study
|
||
| Completed |
NCT05149248 -
Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study
|
Phase 2/Phase 3 | |
| Completed |
NCT00191100 -
Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix
|
Phase 3 | |
| Completed |
NCT00193830 -
High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix
|
Phase 3 | |
| Recruiting |
NCT05742711 -
Efficacy of PENS of the Auricle as an Opioid Sparing Postoperative Analgesic Technique in Cancer Endometrium and Cancer Cervix Patients
|
N/A | |
| Completed |
NCT02865135 -
Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
| Not yet recruiting |
NCT05824494 -
Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors
|
Phase 2 | |
| Active, not recruiting |
NCT05709730 -
Follow-up of Cell Changes in the Cervix
|
||
| Completed |
NCT00193791 -
Concomitant Chemoradiation in Advanced Stage Carcinoma Cervix
|
N/A | |
| Withdrawn |
NCT02312804 -
Ph Ib/BGJ398/Cervix and Other Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03452774 -
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
|
||
| Completed |
NCT00193804 -
A Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix
|
||
| Completed |
NCT04809727 -
Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy
|
N/A |